最新ニュース Teleflex (NYSE:TFX) 株価情報

TELEFLEX INC

Teleflex

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

Teleflex Inc

Teleflex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has risen 116.84% since its last report. The company recently reported that it has 2.42 million shares sold short, which is 8.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743685231_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teleflex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 4.23%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on Teleflex?

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Teleflex, revealing an average target of $153.2, a high estimate of $191.00, and a low estimate of $140.00. Observing a downward trend, the current average is 35.03% lower than the prior average price target of $235.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1743616859_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Teleflex by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$191.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$140.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$149.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$146.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teleflex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teleflex compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Teleflex's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teleflex's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TFX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teleflex analyst ratings.</a>
<h2>Delving into Teleflex's Background</h2>
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
<h3>A Deep Dive into Teleflex's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Teleflex showcased positive performance, achieving a revenue growth rate of 2.78% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teleflex's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -17.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Teleflex's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -3.12%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teleflex's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.87%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Teleflex's debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

5 Analysts Assess Teleflex: What You Need To Know

Citizens Capital Markets analyst David Turkaly reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Market Perform to Market Perform.

News

Reiteration

Citizens Capital Markets Reiterates Market Perform on Teleflexto Market Perform

Teleflex Receives FDA 510(k) Clearance Of The AC3 Range Intra-Aortic Balloon Pump (IABP)

<ul>
<li>The Ringer&#x2122; PBC study is a limited prospective, multi-center, single-arm IDE study, undertaken at four sites in the United States investigating the Ringer&#x2122;&nbsp;PBC for the management of emergent coronary perforations that develop during percutaneous coronary intervention (PCI) procedures. The study enrolled 30 participants, and analysis was performed based upon intention-to-treat. The primary efficacy endpoint required successful Ringer&#x2122; PBC delivery and inflation at the perforation site, control of extravasation (defined as residual Ellis grade 0 or 1), and preservation of antegrade coronary flow (Thrombolysis in Myocardial Infarction [TIMI] grade 2 or 3).</li>
<li>Of 30 participants enrolled, the primary efficacy endpoint was observed in 22 participants (73.3%), with successful Ringer&#x2122;&nbsp;PBC delivery in 26 participants (86.7%). Among those participants with successful delivery, control of extravasation with perfusion was achieved in 22 participants (84.6%). Twelve participants were treated with a covered stent following perforation management with the Ringer&#x2122;&nbsp;PBC. One participant required emergency surgery for complications of pericardiocentesis, and three participants died despite control of extravasation from the index perforation.</li>
</ul>

Health Care

General

Teleflex Announced That The Preliminary Results From Its Ringer PBC IDE Study Were Reported In A Featured Presentation At The CTO Plus Conference

Needham analyst Mike Matson reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Hold to Hold.

Needham Reiterates Hold on Teleflexto Hold

DoorDash Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) shares are trading higher Monday amid the company joining the <a href="https://www.benzinga.com/pressreleases/25/03/n44207026/doordash-tko-group-holdings-williams-sonoma-and-expand-energy-set-to-join-s-p-500-others-to-join-s">S&amp;P 500. </a>
What To Know: After the market close on Friday, S&amp;P Dow Jones Indices announced that DoorDash, TKO Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), Williams-Sonoma Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) and Expand Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) will join the S&amp;P 500. The changes went into effect before the market open on Monday. 
DoorDash shares jumped as much as 7.5% on the news. The four companies will replace Borgwarner Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>), Teleflex Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), Celanese Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) and FMC Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) in the index. 
When companies are added to major indices, they often see an increase in share prices as index funds that track the S&amp;P 500 buy shares of the newly added companies in order to stay aligned with the overall index.
Check This Out: <a href="https://www.benzinga.com/markets/equities/25/03/44212796/palantir-joins-sp-100-after-ai-driven-rally-stock-surges-almost-60-since-trump-victory">Palantir Joins S&amp;P 100 After AI-Driven Rally, Stock Surges Almost 60% Since Trump Victory</a>
<h3 class="wp-block-heading">How To Buy DASH Stock</h3>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in DoorDash's case, it&#8217;s in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
DASH Price Action: <a href="http://benzinga.com/quote/dash">DoorDash shares</a> were up 3.58% at $184.45 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

DASH

DoorDash Stock Is Rising Monday: What's Driving The Action?

Morgan Stanley analyst Patrick Wood maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Overweight and lowers the price target from $275 to $191.

Price Target

Morgan Stanley Maintains Overweight on Teleflex, Lowers Price Target to $191

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup analyst Patrick Donnelly downgraded Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) from Buy to Neutral and maintained the price target of $185. Quest Diagnostics shares closed at $176.95 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Manav Gupta downgraded the rating for Green Plains Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) from Buy to Neutral and announced a $7 price target. Green Plains shares closed at $5.41 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Joseph Stringer downgraded Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) from Buy to Hold and maintained the price target of $10. Pliant Therapeutics shares closed at $1.38 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Craig Bijou downgraded the rating for Teleflex Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Neutral to Underperform and lowered the price target from $235 to $140. Teleflex shares closed at $135.13 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Ramsey El-Assal downgraded AvidXchange Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) from Overweight to Equal-Weight and lowered the price target from $13 to $8. AvidXchange shares closed at $7.42 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Downgrades

Markets

AVDX

GPRE

PLRX

This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

B of A Securities analyst Craig Bijou downgrades Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Neutral to Underperform and lowers the price target from $235 to $140.

B of A Securities Downgrades Teleflex to Underperform, Lowers Price Target to $140

Throughout the last three months, 4 analysts have evaluated Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $158.75, a high estimate of $200.00, and a low estimate of $140.00. Highlighting a 29.13% decrease, the current average has fallen from the previous average price target of $224.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741032042_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Teleflex by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$149.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$146.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$200.00</td>
<td>$227.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teleflex. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teleflex compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Teleflex's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Teleflex's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TFX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teleflex analyst ratings.</a>
<h2>All You Need to Know About Teleflex</h2>
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
<h3>Teleflex: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Teleflex showcased positive performance, achieving a revenue growth rate of 2.78% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teleflex's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -17.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -3.12%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Teleflex's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.87%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Teleflex's debt-to-equity ratio is below the industry average. With a ratio of 0.41, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Teleflex Through The Eyes Of 4 Analysts

Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and lowers the price target from $200 to $149.

Truist Securities Maintains Hold on Teleflex, Lowers Price Target to $149

Wells Fargo analyst Larry Biegelsen maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Equal-Weight and lowers the price target from $214 to $146.

Wells Fargo Maintains Equal-Weight on Teleflex, Lowers Price Target to $146

Piper Sandler analyst Matt O'Brien downgrades Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Overweight to Neutral and lowers the price target from $255 to $140.

Piper Sandler Downgrades Teleflex to Neutral, Lowers Price Target to $140

On Thursday, Teleflex Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) will pursue a plan to separate into two new, independent, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44001713/teleflex-announces-intent-to-separate-into-two-publicly-traded-companies" rel="noreferrer noopener">publicly traded companies</a>:
<ul>
<li>New, independent, publicly traded company (NewCo) consisting of Teleflex&#8217;s Urology, Acute Care, and OEM businesses.</li>
<li>RemainCo will consist of Teleflex&#8217;s Vascular Access, Interventional, and Surgical businesses, focusing on high-growth, high-acuity, primarily hospital-focused emergent end markets.</li>
</ul>
The separation is expected to be completed by mid-2026.
&#8220;Following the separation, RemainCo will be well-positioned to accelerate growth in attractive, primarily hospital-focused, emergent end markets, with a simplified operating model, streamlined manufacturing footprint, and increased management focus,&#8221; said Liam Kelly, Teleflex&#8217;s Chairman, President, and CEO.
RemainCo had approximately $2.1 billion in revenue in 2024.
Concurrently, Teleflex agreed to acquire the Vascular Intervention business of Biotronik SE &amp; Co. KG for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44001607/teleflex-to-acquire-biotroniks-vascular-intervention-business" rel="noreferrer noopener">approximately 760 million euros</a> ($791.6 million). The acquisition is expected to be completed by the end of the third quarter of 2025.
RemainCo is expected to generate constant currency revenue growth of over 6%. RemainCo will have a simplified and nimble operating model with a streamlined manufacturing footprint, transitioning from 19 manufacturing facilities anticipated at Teleflex as of year-end 2025 to 7 facilities at RemainCo post-separation, with the remaining 12 expected to transfer to NewCo.
The transaction is also expected to be accretive to EPS growth, with RemainCo anticipated to deliver double-digit EPS growth in the first full year following the separation.
NewCo, with approximately $1.4 billion in revenue in 2024, is also expected to benefit from a simplified operating model. NewCo is expected to generate low-single digit constant currency revenue growth with a mid-50% adjusted gross margin profile.
Teleflex will initiate an executive search for key management positions at NewCo shortly.
Teleflex also reported fourth-quarter sales of $795.4 million, up 2.8% year over year (+3.2% on constant currency), missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $813.23 million</a>. The medical devices company reported adjusted EPS of $3.89, beating the consensus of $3.86.
Guidance: Teleflex expects 2025 revenue growth of (0.4)% to 0.7%, with adjusted EPS of $13.95-$14.35 versus <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44001824/teleflex-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">consensus of $15.23</a>.
CFO transition: Teleflex announced that Thomas Powell, the company&#8217;s CFO, will retire, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g44001775/teleflex-announces-planned-retirement-of-thomas-powell-as-chief-financial-officer" rel="noreferrer noopener">effective April 1</a>. John R. Deren, currently serving as Corporate Vice President and Chief Accounting Officer, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2.
Price Action: TFX stock is down 21.6% at $139.35 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44008563/donaldson-q2-earnings-miss-aftermarket-and-life-sciences-segments-shine-amid-q2-revenue-dip" target="_blank" rel="noreferrer noopener">Donaldson Q2 Earnings Miss: Aftermarket And Life Sciences Segments Shine Amid Revenue Dip</a></li>
</ul>

Earnings

Large Cap

Guidance

Management

Teleflex Hits 52-Week Low On Plan To Split Into Two Companies, Reports Mixed Q4 Earnings

WIIM

Teleflex shares are trading lower after the company issued FY25 EPS guidance below estimates.

2025 guidance summary
<ul>
<li>GAAP revenue growth guidance range of (0.4)% to 0.7%</li>
<li>Adjusted constant currency revenue growth guidance range of 1.0% to 2.0%, which excludes the 2024 impact from increases in our reserves related to the Italian payback measure pertaining to prior years</li>
<li>GAAP EPS from continuing operations guidance range of $8.85 to $9.25.</li>
<li>Adjusted diluted EPS from continuing operations guidance range of $13.95 to $14.35</li>
</ul>
"In the fourth quarter, we delivered strong double-digit adjusted earnings per share growth" said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer. "The benefits of our diversified portfolio were evident as strong performances from Interventional and Surgical helped offset softness in Interventional Urology revenues. Palette Life Sciences revenues exceeded $75 million in 2025, which was above the $73-$75 million guidance. As announced in a separate press release today, we also took an important step forward in our durable growth strategy with the agreement to acquire substantially all of BIOTRONIK's Vascular Intervention business. This acquisition provides us with a diversified suite of products of coronary and peripheral interventions devices, which complements the Teleflex Interventional business. Also announced today in a separate press release is our intention to separate Teleflex into two publicly traded companies, RemainCo and NewCo. The separation is expected to simplify the operating model, streamline the manufacturing footprint, and increase management focus of each company."

Teleflex Expects 2025 Revenue Growth Of (0.4)% To 0.7%, With Adjusted EPS Of $13.95-$14.35 Versus Consensus Of $15.23

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) reported quarterly earnings of $3.89 per share which beat the analyst consensus estimate of $3.86 by 0.78 percent. This is a 15.09 percent increase over earnings of $3.38 per share from the same period last year. The company reported quarterly sales of $795.41 million which missed the analyst consensus estimate of $813.23 million by 2.19 percent. This is a 2.78 percent increase over sales of $773.90 million the same period last year.

Teleflex Q4 2024 Adj EPS $3.89 Beats $3.86 Estimate, Sales $795.41M Miss $813.23M Estimate

&nbsp;Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition.

Teleflex Announced That Thomas Powell Will Retire As EVP And CFO, Effective April 1. John Deren, Currently The Corporate Vice President And Chief Accounting Officer Of Teleflex, Will Become EVP And CFO, Effective April 2

Teleflex to create a new, independent publicly traded company ("NewCo") consisting of Teleflex's Urology, Acute Care, and OEM businesses.
Teleflex RemainCo ("RemainCo") will consist of Teleflex's Vascular Access, Interventional, and Surgical businesses – focusing on high-growth, high-acuity, primarily hospital-focused emergent end markets.

Teleflex Plans To Separate Into Two Publicly Traded Companies

Legal

Press Releases

TFX INVESTOR INVESTIGATION: A Securities Fraud Investigation has been started on behalf of Teleflex Incorporated Investors – Contact BFA Law before the April 23 Court Deadline

Comments

Teleflex

ニュース

最新ニュース Teleflex (NYSE:TFX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル